Search by Journal

The Japanese Society of Psychiatric Pharmacy

Volume , Issue suppl / 2025
English Article   Japanese Article
  • Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Japanese Article 9th Annual Meeting of the Japanese Society of Psychiatric Pharmacy Delivering medicines that reach the heart for a rainbow-colored future Greetings
椎崇
The Japanese Society of Psychiatric Pharmacy (suppl): 3-3, 2025.
Japanese Article PL. It is ... to the future to shine with ... rainbow color how you give information
椎崇
The Japanese Society of Psychiatric Pharmacy (suppl): 42-42, 2025.
Japanese Article EL1. Medical treatment guidelines and fruit clinical estrangement (evidence-practice gap) of schizophrenia
稲田健
The Japanese Society of Psychiatric Pharmacy (suppl): 43-43, 2025.
Japanese Article EL2. Reactions of drugs, interaction of the psychotropic drug
古郡規雄
The Japanese Society of Psychiatric Pharmacy (suppl): 44-44, 2025.
Japanese Article EL3. Understanding and support developmentally disabled for adulthood
太田晴久
The Japanese Society of Psychiatric Pharmacy (suppl): 45-45, 2025.
Japanese Article EL4. A recent topic about the cognitive-behavioral therapy of the depression: Choice and relation centering on the recovery
菊地俊暁
The Japanese Society of Psychiatric Pharmacy (suppl): 46-46, 2025.
Japanese Article Symposium 1. How are side effect, all of the Clozapine? - Term of side effect measures - Chairman to regard as a laboratory from bedside, both
北村佳久, 北川航平
The Japanese Society of Psychiatric Pharmacy (suppl): 47-47, 2025.
Japanese Article SY1-1. We think about blood poison-related expression mechanism by the Clozapine: Approach from fundamental researches
野田幸裕, 鳥居綾
The Japanese Society of Psychiatric Pharmacy (suppl): 48-48, 2025.
Japanese Article SY1-2. Fundamental researches - Clozapine-induced hypersalivation ... of the clinical pharmacist beginning with a clinical question
峠雄太1), 飛鷹範明1), 吉野祐太2), 種田靖久3), 岡野真梨子2), 草浦裕基2), 池添愛菜3), 山内渉2), 北市清幸3), 上野修一2), 田中守1)
The Japanese Society of Psychiatric Pharmacy (suppl): 49-49, 2025.
Japanese Article SY1-3. Clinical response to food consumption drop with the Clozapine treatment
長浜恭史
The Japanese Society of Psychiatric Pharmacy (suppl): 50-50, 2025.
Japanese Article SY1-4. From - clinical viewpoint to think about side effect measures of the Clozapine -
山本恭平
The Japanese Society of Psychiatric Pharmacy (suppl): 51-51, 2025.
Japanese Article Symposium 2. Challenge the psychiatry medical therapy - advanced age, liver damage, pregnant woman, eating disorders to patients with specific background how; or a term of - Chairman
大久保由衣, 松村俊希
The Japanese Society of Psychiatric Pharmacy (suppl): 52-52, 2025.
Japanese Article SY2-1. "" Medical therapy that does not make it work too much in the elderly people psychiatry practice
竹内啓善
The Japanese Society of Psychiatric Pharmacy (suppl): 53-53, 2025.
Japanese Article SY2-2. The psychiatry medical therapy management in patients with hepatic dysfunction
築地茉莉子
The Japanese Society of Psychiatric Pharmacy (suppl): 54-54, 2025.
Japanese Article SY2-3. Information evaluation and Shared Decision Making in the perinatal psychiatry medical therapy
小澤秀介
The Japanese Society of Psychiatric Pharmacy (suppl): 55-55, 2025.
Japanese Article SY2-4. Practice ... of the pharmacist standing at the intersection of relation ... mind, a body, the pharmacy of the pharmacist for eating disorders
山本ゆりえ
The Japanese Society of Psychiatric Pharmacy (suppl): 56-56, 2025.
Japanese Article Symposium 3. A pharmacist is a term of the Chairman with the key to show "quality of" in psychiatry liaison
坪内清貴, 祖川倫太郎
The Japanese Society of Psychiatric Pharmacy (suppl): 57-57, 2025.
Japanese Article SY3-1. Approach to contribution and delirium to the proper use of the sleeping drug by the pharmacist
重面雄紀
The Japanese Society of Psychiatric Pharmacy (suppl): 58-58, 2025.
Japanese Article SY3-2. Psychiatry pharmacist can do it in the small and medium size body course Hospital without the psychiatrist
鴇崎道則
The Japanese Society of Psychiatric Pharmacy (suppl): 59-59, 2025.
Japanese Article SY3-3. The multi-type of job cooperation and task shift to think about from the activity of the pharmacist in the mental hospital
吉川萌香, 井上裕子
The Japanese Society of Psychiatric Pharmacy (suppl): 60-60, 2025.
Japanese Article Symposium 4. Let's talk at Bar Prova: Prescription suggestions and follow-up for schizophrenia - Listening together with the professor - Words from the chair
葛葉里奈, 中村友喜, 別所千枝
The Japanese Society of Psychiatric Pharmacy (suppl): 61-61, 2025.
Japanese Article SY4-1. With the recent basic schizophrenia medical treatment: Way of thinking of the drug choice mainly on non-fixed form antipsychotics
江角悟
The Japanese Society of Psychiatric Pharmacy (suppl): 62-62, 2025.
Japanese Article SY4-2. ... which regards the next move from positioning - non-fixed form antipsychotics of fixed form antipsychotics as Clozapine in the medical treatment of schizophrenia
石田雄介
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2025.
Japanese Article SY4-3. Possibility ... of the psychology education in psychology education - team approach in medical care for patients with mental disorder
木藤弘子
The Japanese Society of Psychiatric Pharmacy (suppl): 64-64, 2025.
Japanese Article Symposium 5. Term of Japanese mild cure association, the Japanese mental Pharmaceutical Society combination symposium Chairman
伊東俊雅, 保田和哉
The Japanese Society of Psychiatric Pharmacy (suppl): 65-65, 2025.
Japanese Article SY5-1. Information sharing ... with the healthcare worker engaged in the mental domain with a healthcare worker engaged in the case - cancer treatment which was able to contribute to neurologic manifestation control in patients with cancer admitted to the mental hospital
加藤剛
The Japanese Society of Psychiatric Pharmacy (suppl): 66-66, 2025.
Japanese Article SY5-2. Total pain control to support patients' "living and thriving"
鈴木順子1,2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 67-67, 2025.
Japanese Article SY5-3. What is cognitive dysfunction "chemo brain" with cancer treatment?
中川貴之1,2,3), 抱将史1)
The Japanese Society of Psychiatric Pharmacy (suppl): 68-68, 2025.
Japanese Article Symposium 6. Term of the EGUIDE project presents "possibility to have tried new tool "guidelines rate of agreement", and to learn from a practice example" Chairman
井手健太, 清水善仁
The Japanese Society of Psychiatric Pharmacy (suppl): 69-69, 2025.
Japanese Article SY6-1. Summary of the EGUIDE project
井手健太1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 70-70, 2025.
Japanese Article SY6-2. Making and memoir of the guidelines rate of agreement
斉藤善貴
The Japanese Society of Psychiatric Pharmacy (suppl): 71-71, 2025.
Japanese Article SY6-3. If a physician uses the guidelines rate of agreement by clinical practice
川俣安史
The Japanese Society of Psychiatric Pharmacy (suppl): 72-72, 2025.
Japanese Article SY6-4. If a pharmacist uses the guidelines rate of agreement by clinical practice
嶋村悠実
The Japanese Society of Psychiatric Pharmacy (suppl): 73-73, 2025.
Japanese Article Symposium 7. Term of the Chairman generalizing progress of "the inclusion" in now when we reached 2025
中田裕介, 鈴木弘道
The Japanese Society of Psychiatric Pharmacy (suppl): 74-74, 2025.
Japanese Article SY7-1. Expectations for pharmacists in the "A comprehensive community care system that also addresses mental disorders"
池田大輔
The Japanese Society of Psychiatric Pharmacy (suppl): 75-75, 2025.
Japanese Article SY7-2. The practice and future prospects of "A comprehensive community care system that also addresses mental disorders" from the pharmacy's perspective - From the perspective of community-based medication support
神林志穂, 鈴木春菜, 梅宮里奈
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2025.
Japanese Article SY7-3. The spread of "A comprehensive community care system that also addresses mental disorders" and the expertise of hospital pharmacists - Reconsidering their value in multidisciplinary collaboration -
中村友喜
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2025.
Japanese Article WS1. PCP Study Group Commemorative Event Case Study "Let's Consider Better Drug Treatment - Schizophrenia"
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2025.
Japanese Article WS2. Medicine, the reducing practical workshop that it decreases by it of antipsychotics
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2025.
Japanese Article WS3. We will study the study associated with the mental pharmacy
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2025.
Japanese Article WS4. Medicine Hara-related extrapyramidal symptoms measure (DIEPSS) training
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 81-81, 2025.
Japanese Article WS5. EGUIDE project workshop for pharmacists
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 82-82, 2025.
Japanese Article Association between glia cells and neurologic function in the mental disorder
大藪康平
The Japanese Society of Psychiatric Pharmacy (suppl): 83-83, 2025.
Japanese Article The development to extraction and the study of the clinical question by the psychiatry pharmacist: From a viewpoint of treatment continuation and the recovery
荒木遥菜
The Japanese Society of Psychiatric Pharmacy (suppl): 84-84, 2025.
Japanese Article The medication counseling to patients with mental disorder at the health insurance pharmacy and the current situation investigation about the information sharing with the hospital
松村俊希
The Japanese Society of Psychiatric Pharmacy (suppl): 85-85, 2025.
Japanese Article LS1. It is ... for the spread and the implementation of the exit strategy to begin with proper use and exit strategy - entrance of the sleeping drug
高江洲義和
The Japanese Society of Psychiatric Pharmacy (suppl): 86-86, 2025.
Japanese Article LS2. Mainly on a side effect and the tardive dyskinesia of - antipsychotics thinking about schizophrenia treatment that fixed its eyes on the maintenance period -
坪井貴嗣
The Japanese Society of Psychiatric Pharmacy (suppl): 87-87, 2025.
Japanese Article LS3. Understanding of the agitation in Alzheimer's dementia and correspondence ... role ... which "noticed, a pinch-hitter supports it", and is just demanded from a pharmacist
深澤隆1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 88-88, 2025.
Japanese Article LS4. Histories of treatment of fruit clinical ... Lecanemab of the antiamyloid β antibody therapy and multidirectional consideration ...
竹内文一
The Japanese Society of Psychiatric Pharmacy (suppl): 89-89, 2025.
Japanese Article MS-1. We work on the LAI spread to work on by a team
山田雅彦
The Japanese Society of Psychiatric Pharmacy (suppl): 90-90, 2025.
Japanese Article MS-2. Let's begin it; is the LAI introduction instruction by the pharmacist
辛島昌秀
The Japanese Society of Psychiatric Pharmacy (suppl): 91-91, 2025.
Japanese Article P-01. Development of the cognitive usability test using the psychokinesia function test in patients with use of alcohol symptom
富山桜子1), 清水侑真2), 宮浦淳一1,3), 森下夏帆3), 水島久美子3), 内田あおい3), 奥田正英3), 水谷浩明3), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2025.
Japanese Article P-02. An association between GRIK1 genetic polymorphism and effect of treatment of topiramate in the drinking of the alcohol: Systematic review
小武和正1), 松沼悟2)
The Japanese Society of Psychiatric Pharmacy (suppl): 94-94, 2025.
Japanese Article P-03. Look at the rear about the use of the psychology education sheet in the younger patient with the drug overdose experience; mark investigation
木村郁1), 三角純子2), 伊藤香織1)
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2025.
Japanese Article P-04. Fact-finding about the use of commercial drug inappropriateness of the young outpatient in the single department mental hospital
久保慎司, 渡辺智子, 森興一, 小鳥居望
The Japanese Society of Psychiatric Pharmacy (suppl): 95-95, 2025.
Japanese Article P-05. The current situation of our hospital psychiatry liaison team and future problem
田口弘美1), 西村克彦2), 江原誠子3), 高橋晃子4), 石塚雅人1), 中道秀徳1)
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2025.
Japanese Article P-06. Examination of the association between delirium onset and anticholinergic drug risk scale (JARS) for Japan and the predictive value
古賀亮次1), 藤本愛理1), 児玉健介2), 川野菜美3), 井上祥明4), 川野智美1), 関瞭1), 嘉村有紗1), 松崎舞衣7), 櫻井康之5), 児玉真由子6), 下村真代1), 山形真一1)
The Japanese Society of Psychiatric Pharmacy (suppl): 96-96, 2025.
Japanese Article P-07. 1 case ... which came by pain control without relation ... pain-killer with patients admitted to the mental hospital with breast cancer
加藤剛1,2), 清水啓子1), 松本有希1), 渡邊真知子2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2025.
Japanese Article P-08. Efforts to the examination support of the pharmacist in the off-label use of antipsychotics for the delirium
佐々木典子, 兼児敏浩
The Japanese Society of Psychiatric Pharmacy (suppl): 97-97, 2025.
Japanese Article P-09. About a fall fall report and the psychotropic drug of the schizophrenia inpatient
高橋満里, 森亨, 坂本晴香
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2025.
Japanese Article P-10. Questionary survey about the rate of use according to the dosage form of the antipsychotics for patients with schizophrenia and the families and the recognition
徳谷晃1), 高垣淑1), 中村豪志1), 向井馨一郎2), 田中邦佳1), 松永寿人2), 木村健1)
The Japanese Society of Psychiatric Pharmacy (suppl): 98-98, 2025.
Japanese Article P-11. A case which a pharmacist intervened in in the Clozapine introduction to 15-year-old patients
青木涼, 白根真美, 瀬川翼, 藤江直輝, 原田学, 下村好子, 四方佳美
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2025.
Japanese Article P-12. Comparison of the continuance of patients using the sustained-release parenteral injection (Risperidone, Aripiprazole, paliperidone one month preparation, paliperidone three months preparation) in schizophrenia
渡邉温太1), 清水侑真2), 竹内一平3), 半谷眞七子1,2), 藤田潔3), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 99-99, 2025.
Japanese Article P-13. Comparison of the cognitive function with the working situation in patients with schizophrenia and the medical treatment
清水侑真1), 竹内一平2,3), 波多野正和2,4), 半谷眞七子1,2), 藤田潔3), 岩田仲生5), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2025.
Japanese Article P-14. About the usefulness of the cognitive usability test using the psychokinesia function test in patients with schizophrenia
神谷美名1), 清水侑真2), 竹内一平1,3), 波多野正和1,4), 半谷眞七子1,2), 藤田潔3), 岩田仲生5), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 100-100, 2025.
Japanese Article P-15. An attempt of the high-dose olanzapine weight loss and the effect on treatment-resistant schizophrenia
植松拓也1), 石井洋2), 石川貴士3), 石澤文章1), 薄井健介6), 小野寺亮太3), 小原竜1), 海谷夏海4), 加藤貴代子3), 富田隆7), 中山未基3), 郷内琢也1), 中村元昭5)
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2025.
Japanese Article P-16. Effect of the mood stabilizer to give cytopenia derived from Clozapine
佐藤雅也1,3), 和田智仁1), 坂晋3), 藤田康平2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 101-101, 2025.
Japanese Article P-17. Consideration from SGA- durability antipsychosis injection drug 3 comparison between groups
山田雅彦, 末田有土, 横江穂奈美, 高畑大平, 脇のぞみ, 副島理紗子, 桝井章典, 宇治宏美
The Japanese Society of Psychiatric Pharmacy (suppl): 102-102, 2025.
Japanese Article P-18. The schizophrenia medical therapy guidelines rate of agreement and the allied analysis of the contraction of a disease period: Based on EGUIDE
上戸千尋, 滝澤理貴, 井上純孝
The Japanese Society of Psychiatric Pharmacy (suppl): 102-102, 2025.
Japanese Article P-19. Examination of the risk factor of the Clozapine-induced liver enzyme rise
石井香織1), 今泉克明1), 勝海学1), 柏木宏子2), 平林直次2)
The Japanese Society of Psychiatric Pharmacy (suppl): 103-103, 2025.
English Article P-20. Evaluation and Analysis of Long-Acting Injection Invega Hafyera Usage in Hospitalized Patients.
林育弘, 連小茵, 黄馨慧
The Japanese Society of Psychiatric Pharmacy (suppl): 103-103, 2025.
Japanese Article P-21. Change over time of quality of life of the use of Clozapine patients and DAI-10
飛田俊介, 山腰真樹子, 水本唯
The Japanese Society of Psychiatric Pharmacy (suppl): 104-104, 2025.
Japanese Article P-22. Relationship with use of dose of medicine frequency and the multidrug therapy of the antipsychotics in patients with schizophrenia
下山航平1), 花井雄貴2), 横尾卓也1), 田形弘実3), 松本高広1)
The Japanese Society of Psychiatric Pharmacy (suppl): 104-104, 2025.
Japanese Article P-23. About the effectiveness by the supplementation of non-fixed form antipsychotics Brexpiprazole in patients with depression
小林千恵1), 清水侑真2), 竹内一平1,3), 半谷眞七子1,2), 藤田潔3), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 105-105, 2025.
Japanese Article P-24. Investigation about the actual situation of the adverse event that is hard to be manifested of antipsychotics for the bipolar disorder and the cause
堤里菜1), 清水侑真2), 竹内一平3), 堀井里奈4), 波多野正和4), 藤田潔3), 岩田仲生5), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 105-105, 2025.
Japanese Article P-25. Prescription fact-finding of the Clozapine
池田裕, 山本ゆりえ, 山田真大, 田中宏政, 出野良美, 山崎茉惟, 高橋郷, 坂本治彦
The Japanese Society of Psychiatric Pharmacy (suppl): 106-106, 2025.
Japanese Article P-26. Case series study on cancellation of the paliperidone 12 weeks preparation
細川琴実1,2), 黒沢雅広1,2), 真田建史3), 中村暖3), 百賢二1)
The Japanese Society of Psychiatric Pharmacy (suppl): 106-106, 2025.
Japanese Article P-27. One case that oversedation evasion by the limited use and psychoneurotic improvement were obtained by night of the blonanserin patch
石塚雅人1), 西村克彦2), 江原誠子3), 田口弘美1), 高橋晃子4), 中道秀徳1)
The Japanese Society of Psychiatric Pharmacy (suppl): 107-107, 2025.
Japanese Article P-28. A case of bipolar disorder patient successfully treated by switching to lurasidone after developing drug fever due to olanzapine
渡部和幸1), 鈴木啓真2), 星極3,4), 田中義人4), 舟越亮寛1,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 107-107, 2025.
Japanese Article P-29. A case of patients with treatment-resistant schizophrenia that led to home discharge by intervention including the TDM suggestion for the convulsive seizure by the Clozapine
泉実公子1), 坪内清貴1), 竹本弘樹1), 西川達也1), 島名世南1), 奥田丈士2), 小浦真由2), 崔吉道1)
The Japanese Society of Psychiatric Pharmacy (suppl): 108-108, 2025.
Japanese Article P-30. Efforts and task shift of the sustained-release parenteral injection administration schedule grasp
高松侑可1), 関本司1), 馬場寛子1), 高木彰紀2)
The Japanese Society of Psychiatric Pharmacy (suppl): 108-108, 2025.
Japanese Article P-31. Rearward investigation about the treatment continuation after a Clozapine cancellation reason and the fever in our hospital
高橋裕1), 板野美和子1), 首藤雅美1), 芦名孝一2), 赤田卓志朗2)
The Japanese Society of Psychiatric Pharmacy (suppl): 109-109, 2025.
Japanese Article P-32. A case of mixed dementia with sexual deviant behavior due to brexpiprazole
桑原秀徳1,2), 伊東麻衣子2), 阪岡倫行2), 静村知恵2), 市村鴻幸3)
The Japanese Society of Psychiatric Pharmacy (suppl): 109-109, 2025.
Japanese Article P-33. A case that mirtazapine small quantity administration succeeded for the depressive symptom of the dialysis introduction patients
工藤裕太
The Japanese Society of Psychiatric Pharmacy (suppl): 110-110, 2025.
Japanese Article P-34. Effect on recent sleeping drug trend and fall, fall in the mental hospital with the psychiatry acute phase treatment ward
伊東晃尚, 若旅美紀子, 増原朝日, 森田怜子
The Japanese Society of Psychiatric Pharmacy (suppl): 110-110, 2025.
Japanese Article P-35. Adequacy - of the reduction of the effect - benzodiazepine system sleeping drug by the sleeping drug formula reintroduction and the clinical path set prescription
青木竣哉1), 潮田純平1), 高田勝利1), 須鎌建1), 星野達也2), 小池香3), 赤田弘一3), 齋賀孝久3), 佐藤茂樹3), 君和田貢1)
The Japanese Society of Psychiatric Pharmacy (suppl): 111-111, 2025.
Japanese Article P-36. Taking sleeping drug started during hospitalization newly and effect on fall
鎌田朋見1), 肥田裕丈1), 南川友香2), 溝口博之1), 山田清文3), 池末裕明1)
The Japanese Society of Psychiatric Pharmacy (suppl): 111-111, 2025.
Japanese Article P-37. For further improvement of correspondence manual ... patients support according to the disease in the drugstore ... [mental disorder (sleep disorder)] We make it of this
成井繁1,2), 栗原正亮2), 鈴木弘道2), 中田裕介2), 竹内尚子2,3), 黒沢雅広2), 井深宏2), 斎藤庸男2), 真田建史2), 橋場元2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 112-112, 2025.
Japanese Article P-38. It is ... mainly on the situation of medication adequacy business - overlap medication to stop by if caused by Tokorozawa-shi pharmacist society and cooperation of Tokorozawa-shi
加藤剛1,2,4), 杉本美恵子2,4), 大塚正征2,4), 斉藤祐次2,4), 田邉浩一郎2,4), 土井信幸3,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 112-112, 2025.
Japanese Article P-39. The change of the use of the multi-clinical department of antipsychotics: Analysis in the University of Miyazaki faculty of medicine hospital
保田和哉, 池田龍二
The Japanese Society of Psychiatric Pharmacy (suppl): 113-113, 2025.
Japanese Article P-40. Consideration of the disease education by the pharmacist in the acute phase ward
高井英里1), 佐野祐菜1), 西海一生1), 南野希1), 本間久美子1), 青山慎介2)
The Japanese Society of Psychiatric Pharmacy (suppl): 113-113, 2025.
Japanese Article P-41. It is ... about the prescription situation of the inpatient of 1 prescription fact-finding (2024) about the medical therapy of patients with schizophrenia - whole country 51 institution
吉見陽1,2), 宇野準二2), 梅田賢太2), 植草秀介2), 小林真美2), 祖川倫太郎2), 鴇崎道則2), 村野哲雄2), 天正雅美2), 吉尾隆2), 稲田俊也2), 黒沢雅広2)
The Japanese Society of Psychiatric Pharmacy (suppl): 114-114, 2025.
Japanese Article P-42. It is ... about the prescription situation of the outpatient of 2 prescription fact-finding (2024) about the medical therapy of patients with schizophrenia - whole country 36 institution
祖川倫太郎1,2), 宇野準二2), 吉見陽2), 梅田賢太2), 植草秀介2), 小林真美2), 鴇崎道則2), 村野哲雄2), 天正雅美2), 吉尾隆2), 稲田俊也2), 黒沢雅広2)
The Japanese Society of Psychiatric Pharmacy (suppl): 114-114, 2025.
Japanese Article P-43. Importance of medication counseling and the drug history record to a disturbance of consciousness risk to learn from an example
名倉縦子, 郡秀和, 馬淵真梨子, 長尾啓吾, 山本和幸
The Japanese Society of Psychiatric Pharmacy (suppl): 115-115, 2025.
Japanese Article P-44. Report second about enforcement of the psychiatry training in the pharmacy business training
近藤浩樹1), 上條千恵子1), 倉岡徹1), ジョーンズ千絵1), 羽佐田祥浩2), 和田智仁2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 115-115, 2025.
Japanese Article P-45. We evaluate the usefulness of the follow-up after the medication in the new antidepressant based on a psychiatrist and the protocol that we made jointly
清川真帆1), 増田笙吾1), 鵜飼淳1), 田中大智2), 近藤美奈3), 高橋健二4), 高橋千惠子5)
The Japanese Society of Psychiatric Pharmacy (suppl): 116-116, 2025.
Japanese Article P-46. The effect that the psychiatry domain program by the drugstore pharmacist gives to a trainee
神作綾乃1), 久田健登1), 村井佑次1), 坂井信之2), 藤崎玲子1)
The Japanese Society of Psychiatric Pharmacy (suppl): 116-116, 2025.
Japanese Article P-47. Activity ... in role ... multi-type of job of the pharmacist in the clozapine treatment of our hospital and the clozapine committee which collaborated
和田智仁1,5), 舘牧子2,5), 島本健明3,5), 坂井玲子3,5), 森田智也3,5), 内田隆之4,5), 長田成巨4,5), 森厚4,5), 藤田康平4,5)
The Japanese Society of Psychiatric Pharmacy (suppl): 117-117, 2025.
Japanese Article P-48. Assessment about the antipsychotics remedy of the outpatient by the hospital pharmacist and the effect
内山道子, 藤本健太郎
The Japanese Society of Psychiatric Pharmacy (suppl): 117-117, 2025.
Japanese Article P-49. The effect that the draught of medicine monitoring by the pharmacist gives in the prescription trend of the psychopathic ward
清水善仁1), 長澤達也2), 多賀允俊1), 川崎康弘2), 上原隆2), 政氏藤玄1)
The Japanese Society of Psychiatric Pharmacy (suppl): 118-118, 2025.
Japanese Article P-50. A visit is need or ... for request for visit drug control instruction and what kind of patients background ... patients to a mental hospital pharmacist
山本和幸, 行田美咲, 深町明里, 五味和彦
The Japanese Society of Psychiatric Pharmacy (suppl): 118-118, 2025.
Japanese Article P-51. It is ... about the difference of the viewpoint with viewpoint ... Dr. necessary for a pharmacist in a relation to patients refusing medicine
須田修輔
The Japanese Society of Psychiatric Pharmacy (suppl): 119-119, 2025.
Japanese Article P-52. A case which was tied to prescribed medicine decrease and a decrease in draught of medicine use by the home care patient visit drug control instruction of the university hospital psychiatry charge pharmacist
堀井里奈1,2), 波多野正和1,2), 荒木遥菜1), 蟹江孝樹1,2), 鈴木孝幸1,2), 奥村武則3), 竹田奬4), 山田成樹1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 119-119, 2025.
Japanese Article P-53. A case that a diagnosis of the severe depression was reconsidered taking the opportunity of the medication counseling by the pharmacist with the qualification of the master of authorized psychology
嶋村悠実1), 於本崇志1), 朝賀純一1,2), 西田亘3), 大塚耕太郎3), 工藤賢三1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 120-120, 2025.
Japanese Article P-54. About the relation of the meeting a demand situation of the Clozapine prescription in the fur Malaysia's drugstore lengthening of daylight shop and the family pharmacist
上條千恵子1), 近藤浩樹1), 倉岡徹1), ジョーンズ千絵1), 坂井竜太1), 和田智仁2), 羽佐田祥浩2)
The Japanese Society of Psychiatric Pharmacy (suppl): 120-120, 2025.
Japanese Article P-55. Participation of the intracellular signal transduction system going through a α 7 nicotinic acetylcholine receptor in the social nature behavior disorder of the social defeat stress load mouse for the juvenile period
尾崎真優1), 森川和那1), 内田美月1), 阪野新奈1), 尾崎紀夫2), 吉見陽1,2), 野田幸裕1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 121-121, 2025.
Japanese Article P-56. Examination ... of association investigation - effect-like sleep hygiene instruction method of the recognition about the insomniac disease severity and sleep hygiene in the sleeping drug remedy patients
小林聖子1,2), 小柳康弘1,3), 堤箸尚貴1,4), 佐藤幸1,5), 本柳達也1,6), 永井瑛恵1,7), 齋藤寛7)
The Japanese Society of Psychiatric Pharmacy (suppl): 121-121, 2025.
Japanese Article P-57. About a change of the effect of treatment of the case that led to substitution from MPH to LDX by giving information from a drugstore pharmacist
武内美喜子1), 柴田勲2)
The Japanese Society of Psychiatric Pharmacy (suppl): 122-122, 2025.
Japanese Article P-58. The antianxiety effect of the Hochuekkito on LPS-induced pneumonia symptom model mouse and pulmonary disorder improvement effect
植田哲平1), 出石恭久1,2), 田中翔哉1), 藤澤侑生2), 福田亜優2), 北村佳久1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 122-122, 2025.
Japanese Article P-59. Comparison about the effect that the administration of different anticancer agent of the medicine dynamic property gives sensitivity for the social defeat stress of the mouse
茂木啓佑1), 秋永彩華1), 築部涼子1), 安川岳志2), 森本博俊2), 森戸克弥1), 高山健太郎1), 魚住嘉伸2), 長澤一樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 123-123, 2025.
Japanese Article P-60. Intracerebral Clozapine-responsive genetic exploratory study in the phencyclidine-induced schizophrenia-like model mouse
金澤和桜子1), 吉見陽1), 兒島孝明2), 北垣伸治3), 尾崎紀夫4), 池田匡志5), 野田幸裕1)
The Japanese Society of Psychiatric Pharmacy (suppl): 123-123, 2025.
English Article P-61. Enhancing Drug Safety : Insights via Active Reporting & Patient Education
林育弘, 連小茵
The Japanese Society of Psychiatric Pharmacy (suppl): 124-124, 2025.
Japanese Article P-62. Examination of fact-finding of the use of anticholinergic drug in the psychiatry acute phase and the anticholinergic drug risk scale utilization
岩田彩生乃
The Japanese Society of Psychiatric Pharmacy (suppl): 124-124, 2025.
Japanese Article P-63. The case that LAI common knowledge poster was useful
村田峻佑1), 江口万里子2)
The Japanese Society of Psychiatric Pharmacy (suppl): 125-125, 2025.
Japanese Article P-64. It is developed the delirium onset predictive model after the operation using the machine learning technique
尾崎太祐1), 波多野正和2,3), 荒木遥菜3), 清水侑真4), 半谷眞七子1,4), 亀井浩行1,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 125-125, 2025.
Japanese Article P-65. Evaluation of the in paired performance using the psychokinesia function test by the antihistamine remedy in patients with skin disease
佐光敬太1), 清水侑真2), 大河内裕矢1), 井上学3), 平沼翔太3), 榎本尚人3), 榊原幹夫3), 半谷眞七子1,2), 亀井浩行1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 126-126, 2025.
Japanese Article P-66. The effect that supply restrictions of the biperiden hydrochloride gave for the extrapyramidal symptoms of the inpatient
井上純孝1), 鳥山梨佳子2), 島本翔太1), 上戸千尋1), 滝澤理貴1)
The Japanese Society of Psychiatric Pharmacy (suppl): 126-126, 2025.
Japanese Article P-67. Usefulness ... case presentation of the family pharmacist in the medical treatment of the mental disorder and consideration ...
明樂貴文1), 伊藤将2), 阿部洸大2), 長谷川佳孝2), 月岡良太2), 梅田賢太3), 西川洋4), 大石美也2)
The Japanese Society of Psychiatric Pharmacy (suppl): 127-127, 2025.
Japanese Article P-68. The current situation evaluation of the medicine medicine cooperation using a telephone and the drug control summary for the psychiatry inpatient
小林弘典1), 清水善仁1), 飯田澪1), 長澤達也2), 政氏藤玄1)
The Japanese Society of Psychiatric Pharmacy (suppl): 127-127, 2025.
Japanese Article P-69. Fact-finding of the current situation and needs in the communication training of a pharmacist and the pharmacy student
細川智成1,2), 小武和正2), 赤瀬川豊3), 青島周一1,4), 桑原秀徳1,5), 中島俊6)
The Japanese Society of Psychiatric Pharmacy (suppl): 128-128, 2025.
▲